Funding
Retro Biosciences, Backed by Sam Altman, Seeks $1 Billion to Extend Human Lifespan by 10 Years
Retro Biosciences, Sam Altman, Human Lifespan Extension, Biotechnology, Series A Funding, Artificial Intelligence in Healthcare
Light Horse Therapeutics Secures $62M Series A Funding and Partners with Novartis for Cancer Therapies
Light Horse Therapeutics, Novartis, Series A funding, cancer therapies, small molecule therapeutics, precision genetic editing platform
Orbis Medicines Secures €90 Million Series A Funding to Revolutionize Oral Macrocycle Drug Discovery
Orbis Medicines, Series A funding, oral macrocycle drugs, nCycles, biologic drug alternatives, pharmaceutical innovation
Orbis Kicks Off 2025 with €90M Series A Funding in Fierce Biotech Fundraising Tracker
Fierce Biotech Fundraising Tracker 2025, Orbis Series A Funding, Biotech Venture Capital, 2025 Biotech Investments, Series A Funding Rounds
CDC Faces Uncertainty Amid Leadership Change and Funding Threats
CDC, leadership change, funding threats, public health, emerging health threats, Dave Weldon, Dr. Mandy Cohen
Nabla Bio Revolutionizes AI-Driven Protein Design with $26M Series A Funding and Major Pharmaceutical Collaborations
Generative Protein Design, AI-Driven Drug Development, Therapeutic Antibodies, Multipass Membrane Proteins, Pharmaceutical Collaborations, Series A Funding
Arda Therapeutics Secures $43M Series A Funding to Pioneer ADCs for Fibrotic Diseases
Arda Therapeutics, Series A Funding, Fibrotic Diseases, Antibody-Drug Conjugates (ADCs), Eli Lilly, Andreessen Horowitz (a16z)
Superluminal Medicines Secures $120M Series A Funding to Advance Membrane Receptor Drugs into Clinical Trials
Superluminal Medicines, Series A funding, membrane receptor drugs, clinical trials, AI-focused biotech, Eli Lilly investment
Superluminal Secures $120M Series A Funding to Advance Membrane Receptor Drugs into Clinical Trials
Superluminal, Eli Lilly, Series A funding, membrane receptor drugs, clinical trials, biotech, pharmaceuticals
Navigator Medicines Launches with $100 Million Series A Funding to Advance Autoimmune Disease Bispecific Antibody
Navigator Medicines, autoimmune disease, bispecific antibody, Series A funding, RA Capital Management, Forbion